Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens

Praziquantel

Last verified

Veterinary medicinal product: spot-on solution. Distribution category: AVM-GSL (Veterinary Medicines Regulations 2013, Schedule 3). Active substance: Praziquantel.1

In short: questions and answers

Does Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens need a prescription?
Over the counter. As stated in the registration decision.1
Which animals is Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens for?
Cats.1
What is the active substance in Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens?
Praziquantel. ATCvet code: QP52AA01.13
What is the withdrawal period of Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens according to the leaflet?
No withdrawal period is set for this drug: it is not intended for food-producing animals.3
Dispensing
Over the counter1

AVM-GSL: Authorised Veterinary Medicine - General Sale List. No prescription is needed and it may be sold by any retailer.12

Supplied without a prescription. As stated in the registration decision.

Animal species
Cats1
Active substance
Praziquantel
ATCvet code
QP52AA013
Manufacturer
Marketing authorisation holder: Pets Choice Limited

Withdrawal period

No withdrawal period is set for this drug: it is not intended for food-producing animals.3

Summary of product characteristics

Composition

Each 0.5 ml pipette contains:

Active substance:

Praziquantel 20 mg

Excipient(s):

Butylhydroxytoluene (E321) 0.5 mg

For the full list of excipients, see section 6.1.

6.1 List of excipients

Butylhydroxytoluene (E321)

N-methylpyrrolidone

3

Pharmaceutical form

Spot-on solution.

Clear, colourless to pale amber or slightly reddish solution

3

Pharmacological properties

Pharmacotherapeutic group: Anthelmintics, Quinoline derivatives and related substances.

ATCvet code: QP52AA01

5.1 Pharmacodynamics

Praziquantel is effective against all stages of development of intestinal tapeworms. The substance is very rapidly absorbed and distributed throughout the parasite. Both in vivo and in vitro studies have shown that praziquantel causes severe damage to the parasite integument, resulting in contraction and paralysis. There is an almost instantaneous tetanic contraction of the parasite musculature and a rapid vacuolisation of the syncytial tegument. This rapid contraction has been explained by changes in divalent cation fluxes, particularly calcium.

5.2 Pharmacokinetics

Praziquantel is absorbed very rapidly and almost completely in the stomach and small intestine. Studies of the behaviour following oral administration have been conducted in rats, dogs, monkeys, sheep and humans. Depending on species, maximum serum levels are reached within 0.3 to 2 hours. The chemical is evenly distributed to all organs. The elimination half-lives of 14C-praziquantel and its metabolites are between 2 and 3 hours in rats, dogs, monkeys and sheep.

Praziquantel is rapidly metabolised in the liver in both humans and animals with the 4-hydroxycyclohexyl derivative as the main metabolite. Praziquantel is completely eliminated from the body within 48 hours; irreversible binding to body constituents has not been observed. Elimination is in the form of metabolites with virtually no parent compound excreted. Between 40% and 71% of the substance is eliminated in the urine and 13%-30% in the faeces.

3

Target species

Cats.

3

Indications

For the treatment of tapeworms of cats. The product is effective against mature and immature forms of Dipylidium caninum and Taenia species. The product is also effective against Echinococcus multilocularis.

3

Dosage

Dosage and Treatment Schedule

The minimum dose rate is 8 mg/kg bodyweight, which equates to 1 tube per 2.5 kg bodyweight.

BodyweightNumber of TubesQuantity of Praziquantelmg/kg bw
1 - 2.5 kg120 mg8 - 20
>2.5 - 5 kg240 mg8 - 16
>5 kg360 mgmaximum 12

Method of Administration

Polypropylene pipettes

Remove one tube from the package. Hold tube in an upright position and snap off the cap, opening the tube.

Part the hair on the cat's neck at the base of the skull until the skin is visible.

Place the tip of the tube on the skin and squeeze firmly several times to empty the contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the cat to lick the product.

To minimise the possibility of run-off after application of more than one pipette, it is advised that the applications should be performed slowly to allow absorption and that it may be advisable to allow the contents of the previous pipette to be absorbed before applying another.

Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.

Flea control: flea infestations can be controlled by the regular use of effective flea control remedies.

Mice control: if cats roam and hunt, contact with, and consumption of, mice and subsequent re-infestation with Taenia taeniaeformis is impossible to prevent.

It is recommended to re-apply the product when signs of tapeworm infestation re- appear or at monthly intervals.

3

Contraindications

Do not use on cats weighing less than 1 kg bodyweight.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3

Adverse reactions

On very rare occasions a transient local reaction such as scurf (flaking skin) or mild exudation (weeping) may be observed at the application site following treatment.

On very rare occasions salivation may occasionally occur if the cat licks the application site immediately after treatment, as the product is bitter tasting. This is not a sign of intoxication and disappears after a short time without treatment.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

3

Warnings

i) Special precautions for use in animals

Care should be taken to avoid the contents of the tube coming into contact with the eyes or mouth of the recipient animal.

For external use only.

ii) Special precautions to be taken by the person administering the medicinal product to animals

This product can be irritant to the skin and eyes.

Care should be taken to prevent contact of the solution with the skin, eyes and mouth, including hand-to eye and hand-to mouth contact.

If contact with the skin occurs, wash off any skin contamination with soap and water immediately.

If accidental contact occurs with the eyes, flush the affected eyes thoroughly with clean fresh water.

In the event of skin or eye contact, seek medical advice if irritation persists and show the Doctor this package.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Laboratory studies with the excipient N-methyl-2-pyrrolidone in rabbits and rats have shown evidence of teratogenic, foetotoxic, maternotoxic and reprotoxic effects. Avoid direct contact with the product and application site.

Do not stroke or groom animals until area of application is dry (at least 1 hour after application).

Wash hands thoroughly after use.

Do not eat, drink or smoke during application.

Store away from food, drink or animal feedingstuffs.

iii) Other precautions

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology). If the cat has visited areas where Echinococcus spp. are prevalent, a veterinarian should be consulted.

Keep recently treated pets away from varnished, polished, plastic or leather surfaces.

3

Use during pregnancy, lactation or lay

There are no contra-indications against use during pregnancy and lactation.

3

Interactions

No incompatibility has been observed between this product at the recommended dose and a range of common veterinary treatments.

3

Overdose

Overdosing can lead to slight skin reactions which disappear without treatment within a few days.

3

Special warnings

Do not allow recently treated animals to groom each other.

3

Withdrawal period

Not applicable as the product is not indicated for the treatment of food producing animals.

3

Incompatibilities

None known.

3

Immediate packaging

Polypropylene pipettes

White polypropylene tube with a snap-off tab.

Blister pack of 2 or 4 unit dose tubes in a carton.

3

Storage

Store away from food, drink and animal feeding stuffs.

Do not store above 25°C.

Store in a dry place in the original package.

3

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale:

Thermoformed pipette: 2 years Polypropylene pipette: 18 months

3

Disposal of unused product

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

3

Additional information

Vm 52797/5013

9 DATE OF FIRST AUTHORISATION

01 April 2015

10 DATE OF REVISION OF THE TEXT

October 2025

3

Registration holder

Pets Choice Limited

Brentwood House, Lower Philips Road

Whitebirk Industrial Estate

Blackburn

Lancashire

BB1 5UD

United Kingdom

3

Regulations

Sources

  1. VMD Product Information Database: Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens, 52797/5013 UK Veterinary Medicines Directorate (OGL v3.0), checked 2026-10-04 archived copy from 2026-10-04
  2. The Veterinary Medicines Regulations 2013, Schedule 3 (categories of veterinary medicinal products) UK Government, legislation.gov.uk, checked 2026-10-04 archived copy from 2026-10-04
  3. Summary of Product Characteristics: Bob Martin Clear Wormer 20 mg Spot-on Solution for Cats and Kittens UK Veterinary Medicines Directorate, SPC of the marketing authorisation holder, checked 2026-10-04 archived copy from 2026-10-04

Other products with the same active substance

All products with this active substance (10)

The same active substance in other countries

These are different medicines with different authorisations. The dispensing status is the one on each product's own page, which gives its basis. The leaflet of the product in hand applies.

Spain

All products with this active substance (2)

Poland

Ukraine